“Long Neuro COVID-19 is hypothesized to follow SARS-CoV-2 virus specific pathophysiological changes, with aberrant inflammatory disease and immune responses post-acute infection, similar to that reported with other viral infections including Epstein-Barr Virus (EBV) and associated Chronic Fatigue Syndrome2. Notably patients who had COVID-19 while also infected with EBV were at an increased risk of memory loss7 and EBV infection increases the risk of autoimmune diseases such as Multiple Sclerosis (MS)8 and associated adverse neurological manifestations. ANP’s immunomodulatory drug ATL1102 has previously demonstrated biologic activity in MS patients…”
Itsa :No brainer..
ANP Price at posting:
10.0¢ Sentiment: Buy Disclosure: Held
